Medgenics' Receives Allowance for Key European Patent

Follows Similar U.S. Patent for Biopump Protein Therapy Technology and Expands Intellectual Property Portfolio

Medgenics has three long-acting protein therapy products in development based on this technology:

EPODURE (now completing a Phase I/II dose-ranging trial) to produce and deliver erythropoietin for many months from a single administration, has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for six to more than 36 months;